PMID- 27602773
OWN - NLM
STAT- MEDLINE
DCOM- 20180221
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 43
DP  - 2016 Oct 25
TI  - Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a 
      systematic review and meta-analysis.
PG  - 70128-70142
LID - 10.18632/oncotarget.11806 [doi]
AB  - We conducted a pooled analysis comparing the efficacy of an immunohistochemistry 
      (IHC) assay using the D5F3 antibody with that of fluorescence in situ 
      hybridization (FISH) for detecting ALK gene rearrangement in NSCLC patients. A 
      total of 32 studies involving 5805 samples were included in this review. Pooled 
      sensitivity for D5F3 IHC was 0.97 (95%CI: 0.93-0.98), specificity was 0.99 
      (95%CI: 0.98-1.00), PLR was 119.20 (95%CI: 57.79-245.89), NLR was 0.03 (95%CI: 
      0.02-0.07), DOR was 3526.66 (95%CI: 1344.71-9249.03), and AUROC was 1.00 (95%CI: 
      0.99-1.00). Meta-regression revealed that specimen type was a source of 
      heterogeneity for specificity, and specimen type and FISH signal distance were 
      sources of heterogeneity in the joint model. Subgroup analysis revealed that 
      sensitivity and specificity were higher when the FISH signal distance standard 
      was >/= 2 than when it was >/= 1. Sensitivity was higher for tumor specimens than for 
      cell specimens; specificity was higher for cell specimens than for tumor 
      specimens. In conclusion, the D5F3 IHC assay was nearly as effective as FISH for 
      detection of ALK gene rearrangement in NSCLC patients.
FAU - Ma, Hu
AU  - Ma H
AD  - Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 
      563000, China.
FAU - Yao, Wen-Xiu
AU  - Yao WX
AD  - Department of Oncology, Affiliated Cancer Hospital of Medical School, University 
      of Electronic Science and Technology of China, Sichuan Cancer Hospital and 
      Institute & Cancer, The Second People's Hospital of Sichuan Province, Chengdu, 
      610000, China.
FAU - Huang, Lang
AU  - Huang L
AD  - Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 
      563000, China.
FAU - Jin, Su-Han
AU  - Jin SH
AD  - Affiliated Stemmatological Hospital of Zunyi Medical University, Zunyi 563000, 
      China.
FAU - Liu, Da-Hai
AU  - Liu DH
AD  - Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 
      563000, China.
FAU - Liu, Yuan
AU  - Liu Y
AD  - Department of Pharmacology and Key Laboratory of Basic Pharmacology of Ministry 
      of Education, Zunyi Medical University, Zunyi 563000, China.
FAU - Tian, Xu
AU  - Tian X
AD  - Chongqing Cancer Hospital and Institute, Chongqing, 40030, China.
FAU - Tian, Jin-Hui
AU  - Tian JH
AD  - Evidence-Based Medicine Center of Lanzhou University, Lanzhou, 730000, China.
FAU - Zhou, Jian-Guo
AU  - Zhou JG
AD  - Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 
      563000, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antibodies)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Antibodies/*immunology
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics
MH  - Receptor Protein-Tyrosine Kinases/*genetics
PMC - PMC5342540
OTO - NOTNLM
OT  - ALK
OT  - D5F3
OT  - NSCLC
OT  - diagnostic accuracy
OT  - meta-analysis
COIS- CONFLICTS OF INTEREST There is no conflict of interest for any author regarding 
      the publication of this manuscript.
EDAT- 2016/09/08 06:00
MHDA- 2018/02/22 06:00
PMCR- 2016/10/25
CRDT- 2016/09/08 06:00
PHST- 2016/06/06 00:00 [received]
PHST- 2016/08/13 00:00 [accepted]
PHST- 2016/09/08 06:00 [pubmed]
PHST- 2018/02/22 06:00 [medline]
PHST- 2016/09/08 06:00 [entrez]
PHST- 2016/10/25 00:00 [pmc-release]
AID - 11806 [pii]
AID - 10.18632/oncotarget.11806 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Oct 25;7(43):70128-70142. doi: 10.18632/oncotarget.11806.